Identifiants & Marche
Ticker
BLU
ISIN
CA07987C2040
CIK
0001259942
Bourse
NASDAQ
Devise
USD
Entreprise
Pays
CA
Siege
N/A
Fondee
N/A
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.